Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Net Income - Minority (2021 - 2023)

Zentalis Pharmaceuticals has reported Net Income - Minority over the past 3 years, most recently at -$107000.0 for Q4 2023.

  • For Q4 2023, Net Income - Minority rose 51.58% year-over-year to -$107000.0; the TTM value through Dec 2023 reached -$107000.0, up 51.58%, while the annual FY2023 figure was -$107000.0, 51.58% up from the prior year.
  • Net Income - Minority for Q4 2023 was -$107000.0 at Zentalis Pharmaceuticals, up from -$129000.0 in the prior quarter.
  • Over five years, Net Income - Minority peaked at -$107000.0 in Q4 2023 and troughed at -$528000.0 in Q4 2021.
  • A 3-year average of -$217333.3 and a median of -$159500.0 in 2023 define the central range for Net Income - Minority.
  • Biggest five-year swings in Net Income - Minority: skyrocketed 58.14% in 2022 and later surged 51.58% in 2023.
  • Year by year, Net Income - Minority stood at -$528000.0 in 2021, then skyrocketed by 58.14% to -$221000.0 in 2022, then surged by 51.58% to -$107000.0 in 2023.
  • Business Quant data shows Net Income - Minority for ZNTL at -$107000.0 in Q4 2023, -$129000.0 in Q3 2023, and -$141000.0 in Q2 2023.